Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

The EVER genes - the genetic etiology of carcinogenesis in epidermodysplasia verruciformis and a possible role in non-epidermodysplasia verruciformis patients.

Kalińska-Bienias A, Kowalewski C, Majewski S.

Postepy Dermatol Alergol. 2016 Apr;33(2):75-80. doi: 10.5114/ada.2016.59145. Epub 2016 May 16. Review.

2.

Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials.

Mehanna H, Franklin N, Compton N, Robinson M, Powell N, Biswas-Baldwin N, Paleri V, Hartley A, Fresco L, Al-Booz H, Junor E, El-Hariry I, Roberts S, Harrington K, Ang KK, Dunn J, Woodman C.

Head Neck. 2016 Apr;38 Suppl 1:E1863-9. doi: 10.1002/hed.24336. Epub 2016 Jan 8.

3.

Chromosomal radiosensitivity of human immunodeficiency virus positive/negative cervical cancer patients in South Africa.

Herd O, Francies F, Kotzen J, Smith T, Nxumalo Z, Muller X, Slabbert J, Vral A, Baeyens A.

Mol Med Rep. 2016 Jan;13(1):130-6. doi: 10.3892/mmr.2015.4504. Epub 2015 Nov 5.

4.

Restoration of epigenetically silenced SULF1 expression by 5-aza-2-deoxycytidine sensitizes hepatocellular carcinoma cells to chemotherapy-induced apoptosis.

Shire A, Lomberk G, Lai JP, Zou H, Tsuchiya N, Aderca I, Moser CD, Gulaid KH, Oseini A, Hu C, Warsame O, Jenkins RB, Roberts LR.

Med Epigenet. 2015 Jan-Apr;3(1):1-18.

5.

A coding variant in TMC8 (EVER2) is associated with high risk HPV infection and head and neck cancer risk.

Liang C, Kelsey KT, McClean MD, Christensen BC, Marsit CJ, Karagas MR, Waterboer T, Pawlita M, Nelson HH.

PLoS One. 2015 Apr 8;10(4):e0123716. doi: 10.1371/journal.pone.0123716. eCollection 2015.

6.

Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.

Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, Constantinidis TC; HERMES study group.

PLoS One. 2015 Mar 20;10(3):e0119755. doi: 10.1371/journal.pone.0119755. eCollection 2015.

7.

Genetic variants in DNA repair genes as potential predictive markers for oxaliplatin chemotherapy in colorectal cancer.

Kap EJ, Seibold P, Richter S, Scherer D, Habermann N, Balavarca Y, Jansen L, Becker N, Pfütze K, Popanda O, Hoffmeister M, Ulrich A, Benner A, Ulrich CM, Burwinkel B, Brenner H, Chang-Claude J.

Pharmacogenomics J. 2015 Dec;15(6):505-12. doi: 10.1038/tpj.2015.8. Epub 2015 Mar 17.

PMID:
25778469
8.

Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases.

Choi UY, Kang JS, Hwang YS, Kim YJ.

Exp Mol Med. 2015 Mar 6;47:e144. doi: 10.1038/emm.2014.110. Review.

9.

Genetic association between the HIF-1α P582S polymorphism and cervical cancer risk: a meta analysis.

Zhu J, Cheng X, Xie R, Chen Z, Li Y, Lin G, Liu J, Yang Y.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):6085-90. eCollection 2014. Review.

10.

High incidence of oncogenic HPV genotypes found in women from Southern Brazil.

Entiauspe LG, Silveira M, Nunes EM, Basgalupp SP, Stauffert D, Dellagostin OA, Collares T, Seixas FK.

Braz J Microbiol. 2014 Aug 29;45(2):689-94. eCollection 2014.

11.

Polymorphisms in immune mediators associate with risk of cervical cancer.

Zhang Z, Fye S, Borecki IB, Rader JS.

Gynecol Oncol. 2014 Oct;135(1):69-73. doi: 10.1016/j.ygyno.2014.07.106. Epub 2014 Aug 12.

12.

Clinical implications of interferon-γ genetic and epigenetic variants.

Smith NL, Denning DW.

Immunology. 2014 Dec;143(4):499-511. doi: 10.1111/imm.12362. Review.

13.

Replicative DNA polymerase mutations in cancer.

Heitzer E, Tomlinson I.

Curr Opin Genet Dev. 2014 Feb;24:107-13. doi: 10.1016/j.gde.2013.12.005. Epub 2014 Feb 26. Review.

14.

The LKB1 tumor suppressor differentially affects anchorage independent growth of HPV positive cervical cancer cell lines.

Mack HI, Munger K.

Virology. 2013 Nov;446(1-2):9-16. doi: 10.1016/j.virol.2013.07.009. Epub 2013 Aug 7.

15.

Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents.

Sudenga SL, Wiener HW, Shendre A, Wilson CM, Tang J, Shrestha S.

Hum Immunol. 2013 Dec;74(12):1696-700. doi: 10.1016/j.humimm.2013.08.010. Epub 2013 Aug 21.

16.

Racial differences in the incidence and clearance of human papilloma virus (HPV): the HPV in men (HIM) study.

Schabath MB, Villa LL, Lin HY, Fulp WJ, Akogbe GO, Abrahamsen ME, Papenfuss MR, Lazcano-Ponce E, Salmerón J, Quiterio M, Giuliano AR.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1762-70. doi: 10.1158/1055-9965.EPI-13-0303. Epub 2013 Jul 19.

17.

RPS19 and TYMS SNPs and Prevalent High Risk Human Papilloma Virus Infection in Nigerian Women.

Famooto A, Almujtaba M, Dareng E, Akarolo-Anthony S, Ogbonna C, Offiong R, Olaniyan O, Wheeler CM, Doumatey A, Rotimi CN, Adeyemo A, Adebamowo CA.

PLoS One. 2013 Jun 27;8(6):e66930. doi: 10.1371/journal.pone.0066930. Print 2013.

18.

Genetic susceptibility of cervical cancer.

Chen X, Jiang J, Shen H, Hu Z.

J Biomed Res. 2011 May;25(3):155-64. doi: 10.1016/S1674-8301(11)60020-1.

19.

Nucleotide variation in IL-10 and IL-12 and their receptors and cervical and vulvar cancer risk: a hybrid case-parent triad and case-control study.

Hussain SK, Madeleine MM, Johnson LG, Du Q, Galloway DA, Daling JR, Malkki M, Petersdorf EW, Schwartz SM.

Int J Cancer. 2013 Jul;133(1):201-13. doi: 10.1002/ijc.28000. Epub 2013 Feb 12.

20.

A population-based study of DNA repair gene variants in relation to non-melanoma skin cancer as a marker of a cancer-prone phenotype.

Ruczinski I, Jorgensen TJ, Shugart YY, Schaad YB, Kessing B, Hoffman-Bolton J, Helzlsouer KJ, Kao WH, Wheless L, Francis L, Alani RM, Strickland PT, Smith MW, Alberg AJ.

Carcinogenesis. 2012 Sep;33(9):1692-8. doi: 10.1093/carcin/bgs170. Epub 2012 May 11.

Items per page

Supplemental Content

Write to the Help Desk